0001104659-24-024609.txt : 20240215 0001104659-24-024609.hdr.sgml : 20240215 20240215183701 ACCESSION NUMBER: 0001104659-24-024609 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221114 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dye Justin CENTRAL INDEX KEY: 0001654539 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-55450 FILM NUMBER: 24645292 MAIL ADDRESS: STREET 1: C/O MEDICINE MAN TECHNOLOGIES, INC. STREET 2: 4880 HAVANA STREET, SUITE 201 CITY: DENVER STATE: CO ZIP: 80239 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Medicine Man Technologies, Inc. CENTRAL INDEX KEY: 0001622879 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 465289499 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 865 N. ALBION ST. STREET 2: SUITE 300 CITY: DENVER STATE: CO ZIP: 80220 BUSINESS PHONE: 303-371-0387 MAIL ADDRESS: STREET 1: 865 N. ALBION ST. STREET 2: SUITE 300 CITY: DENVER STATE: CO ZIP: 80220 4/A 1 tm242104-14_4aseq1.xml OWNERSHIP DOCUMENT X0508 4/A 2022-11-14 2022-11-16 0 0001622879 Medicine Man Technologies, Inc. SHWZ 0001654539 Dye Justin C/O MEDICINE MAN TECHNOLOGIES, INC. 865 N. ALBION ST., STE 300 DENVER CO 80220 1 0 1 0 0 Common Stock 2022-11-15 4 A 0 198484 1.57 A 489452 D Common Stock 2023-02-13 4 P 0 500000 1.5 A 500000 I See footnote Common Stock 2023-09-29 4 A 0 130801 0 A 1616363 D On November 14, 2022, the reporting person filed a Form 4 that erroneously reported a purchase of 187,484 of shares of Common Stock on November 15, 2022. In fact, as reported in this amendment, the purchase made on November 15, 2022, involved 198,484 shares of common stock. This filing properly reflects the correct number of shares acquired and beneficially owned by the reporting person in and following the reported transaction. The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.34 to $1.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the numbers of shares purchased at each separate price within the range set forth in this footnote. On February 15, 2023, the reporting person filed a Form 4 that erroneously reported a purchase of 500,000 of Common Stock on February 13, 2023, as directly owned by the reporting person. In fact, as reported in this amendment, the purchase made on February 13, 2024, represents shares of common stock held by Dye Capital LLLP ("Dye LLLP"). As the managing partner of Dye LLLP, Mr. Dye has voting and investment control over the securities held by Dye LLLP. Mr. Dye disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein. This filing properly reflects the correct number of shares acquired and beneficially owned by the reporting person in and following the reported transaction. The issuer granted the reporting person shares of common stock with an aggregate value of $103,333 (based on the closing price of the common stock on the OTCQX Best Market on September 29, 2023) for services on the board of directors. On October 6, 2023, the reporting person filed a Form 4 that erroneously reported the Amount of Securities Beneficially Owned Following Reported Transaction of 1,998,863 shares of Common Stock directly owned by the reporting person. In fact, as reported in this amendment, the Amount of Securities Beneficially Owned Following Reported Transaction involved 1,616,363 shares of Common Stock. This filing properly reflects the correct number of shares acquired and beneficially owned, directly, by the reporting person in and following the reported transaction. /s/ Daniel R. Pabon Attorney-in-Fact for Justin C. Dye 2024-02-15